BioScienceBioScience
Product Integrity Program
Anti-Counterfeiting Project for Baxter BioScience
Product Integrity Program
Anti-Counterfeiting Project for Baxter BioScience
Plasma Product Biotechnology 12 May 2009
Plasma Product Biotechnology 12 May 2009
Presentation ObjectivesPresentation Objectives• Introduction
2Confidential
• BioScience– History of Events– Product Integrity Program– Next Steps
• Suggestions by Experts
• Background– Counterfeiting is a Worldwide Issue– Impact to our Business
• Questions & Answers
InquiryInquiry
3Confidential
• How many of you have had counterfeiting issues?
• Does your company have a product integrity program?
• In parts of Africa, Asia, and Latin America over 30% of the drug supply is likely counterfeit
• In some Soviet republics, drug counterfeiting is higher than 20%
• In developing nations, drug counterfeiting is, on average, over 10%
Source: WHO International Medical Products Anti-Counterfeiting Task Force (IMPACT)
• In parts of Africa, Asia, and Latin America over 30% of the drug supply is likely counterfeit
• In some Soviet republics, drug counterfeiting is higher than 20%
• In developing nations, drug counterfeiting is, on average, over 10%
Source: WHO International Medical Products Anti-Counterfeiting Task Force (IMPACT)
4Confidential
Counterfeiting is a Worldwide IssueCounterfeiting is a Worldwide IssueCounterfeiting is an ever-present and growing issue within the pharmaceutical community worldwide worldwide
According to the World Health According to the World Health Organization (WHO)Organization (WHO)……
# of
Ope
n FD
A C
ases
FDA Counterfeit Open Investigations 1997 FDA Counterfeit Open Investigations 1997 -- 20042004
Source: 1. Combating Counterfeit Drugs: A Report of the
FDA, 2/18/2004
• As much as 50% of the drug supply in China is likely counterfeit
• In the developing countries such as Argentina, Columbia, and Mexico, 40% is suspected
Source: New FDA Initiative to Combat Counterfeit Drugs
• As much as 50% of the drug supply in China is likely counterfeit
• In the developing countries such as Argentina, Columbia, and Mexico, 40% is suspected
Source: New FDA Initiative to Combat Counterfeit Drugs
According to the According to the FDAFDA……
Fake Pfizer medicines have been found in approximately 70 countries around the worldPfizer medicines that have been counterfeited include:
– Lipitor– Viagra– Norvasc– Zoloft– Celebrex– Aricept– Diflucan
Counterfeiting is a Worldwide IssueCounterfeiting is a Worldwide IssuePfizerPfizer’’s Growing Counterfeiting Problem s Growing Counterfeiting Problem --
US Lipitor Recall:Lipitor (indicated for high cholesterol) is the most prescribed medicine in the worldIn April 2003, patients complained that tablets had bitter taste and dissolved quickly in the mouthFDA recalled 18 million Lipitor tablets, the largest recall of counterfeit medicine in the US to dateCounterfeit Lipitor was found in 15 US states
UK Lipitor Recall:In July 2005, 3.6 million tablets (120K packs) were recalled due to counterfeiting claims106 UK pharmacies participated in the recallApproximately 50% of the returned medicine proved to be counterfeit
CounterfeitCounterfeit NorvascNorvasc 5Confidential
The absence of deterrent legislation in many countries also encourages counterfeiters since there is no fear of being apprehended and prosecuted.
Counterfeiting is a Worldwide IssueCounterfeiting is a Worldwide IssueRoot of the Problem Root of the Problem --
Counterfeiting medicines is a lucrative businessThe production of counterfeit drugs need not occur in large infrastructures or facilities. The majority of the counterfeiters apprehended so far carried out their activities in ordinary households, small cottage industries, or in backyards.
When prices of medicines are high and price differentials between identical products exist there is a greater incentive for the consumer to seek medicines outside the normal supply system.
Counterfeiting of medicines is a hugely lucrative business due to the continued high demand for medicines and low production costs.
In many countries the official supply chain fails to reach many communities, especially in rural areas. Poverty, and the lack of an official supply chain, are major factors in creating markets for counterfeit products.Source: World Health Organization, International Medical Products Anti-Counterfeiting Task Force (IMPACT)
5Confidential
Counterfeited BioScience Products:Counterfeited BioScience Products:
• Counterfeit Baxter label (Immunate) applied to AHF-M product vial, to receive a higher price(cross-labeling, up-labeling)
7Confidential
• BioScience products counterfeited in South America involving several counterfeiting scenarios: – Counterfeiting included tampering, cross-labeling and up-labeling
• Reused albumin containers by filling bottles with saline solution and capping with newly purchased caps (tampering)
• Local albumin manufacturer applied a counterfeit Baxter labelto their product to capitalize on Baxter’s position in the market, receiving a higher price (Biosimilar)
• Counterfeit 1000 IU Recombinate on an authentic 500 IU product vial, to receive a higher price (cross-labeling involving Baxter product and labels)
– Detection of the events is limited
BioScience Incidents in South AmericaBioScience Incidents in South AmericaCounterfeiting, Tampering Counterfeiting, Tampering
Product Booklet Label: Poor Condition vs. Intact
Injection Target: Small vs. Large Extension
Reused albumin containers by filling used bottles with saline Reused albumin containers by filling used bottles with saline solution and capping with newly purchased capssolution and capping with newly purchased caps
Counterfeit Baxter
Counterfeit Baxter
8Confidential
BioScience Incidents in South AmericaBioScience Incidents in South AmericaCounterfeiting (Biosimilar) Counterfeiting (Biosimilar)
Counterfeit
Baxter
Local albumin manufacturer applied a counterfeit Baxter label toLocal albumin manufacturer applied a counterfeit Baxter label totheir product to capitalize on Baxtertheir product to capitalize on Baxter’’s position in the market, s position in the market, receiving a higher pricereceiving a higher price
9Confidential
BioScience Incidents in South AmericaBioScience Incidents in South AmericaCounterfeiting, CrossCounterfeiting, Cross--labeling & Uplabeling & Up--labelinglabeling
Counterfeit Baxter Immunate label applied to AHFCounterfeit Baxter Immunate label applied to AHF--M product vial, M product vial, to receive a higher priceto receive a higher price
10Confidential
Baxter Recombinate 1000 IU label applied to Recombinate 500 IU Baxter Recombinate 1000 IU label applied to Recombinate 500 IU product vial, to receive a higher priceproduct vial, to receive a higher price
11Confidential
BioScience Incidents in South AmericaBioScience Incidents in South AmericaCounterfeiting, UpCounterfeiting, Up--labelinglabeling
Voice of the CustomerVoice of the CustomerRisks of not moving forward with antiRisks of not moving forward with anti--counterfeiting measurescounterfeiting measures
12Confidential
Loss of Market Share
Loss of Loss of Market ShareMarket Share
Impact to Patient Safety
Impact to Impact to Patient Patient SafetySafety
Loss of Consumer Confidence
Loss of Loss of Consumer Consumer ConfidenceConfidence
Increased Regulatory Exposure
Increased Increased Regulatory Regulatory ExposureExposure
Impact to Customer
Needs
Impact to Impact to Customer Customer
NeedsNeeds
Loss of Control of Product Integrity
Loss of Loss of Control of Control of Product Product IntegrityIntegrity
BioScience moves forward…
BioScience Product Integrity Program:BioScience Product Integrity Program:Comprised of Implementing Three Distinct Measures Comprised of Implementing Three Distinct Measures --
Track & Trace Features
Tamper Evident Features
Product Authentication
Features
Product Integrity
Maintain Distribution Chain Integrity
• Distribution Monitoring
• Serialization
• ePedigree
Maintain Product Purity• Flip off caps on bottles serve
as tamper evident device
• Investigated additional tamper evident measures (e.g., tapes)
Authenticate Product• New vial labels
• New unit cartons
• Branded vial caps
13Confidential
Product IntegrityProduct IntegrityProject FocusProject Focus
Safeguard the Safeguard the Distribution Distribution ChainChain
BioScience Product Integrity Program:BioScience Product Integrity Program:Product Authentication & Security Features Product Authentication & Security Features --
• To deter potential counterfeiting, up-labeling, cross-labeling, and tampering
14Confidential
• Multi-layered approach using overt, semi-covert, & covert features
• Standard product integrity features were identified for:Labels
CapsUnit Cartons
• Standard features approved by the Product Brand Integrity Team for use on BioScience products– Ensures continuity and consistency of features– Simplifies implementation– Maximizes customer awareness & sensitivity of
authentic product
Product Integrity Features:Product Integrity Features:Product Authentication & Security Features Product Authentication & Security Features --
• Select BioScience Product Labels
15Confidential
– The Baxter wordmark (logo) will be contained in a stripe using color-shifting ink on the label (overt)
– Security slits are placed around the perimeter of the base label, which causes part or all of the label to be destroyed if removed from the bottle (overt), or
– Void effect which upon removal leaves the label with the phrase "void" again mitigating re-use (overt)
– Covert features are not visible to the customer, but allow Baxter to confirm a product in the field is ours(NOTE: These will remain covert)
• Select BioScience Product Unit Cartons– Near-transparent varnish with the Baxter logo (overt)
– Micro-text (semi-covert feature)
Features for ADVATEFeatures for ADVATE
16Confidential
Uni
t Car
ton
Vial
Lab
el
Features for NG AlbuminFeatures for NG Albumin
17Confidential
Baxter logo printed with color-shifting background
Security slits to Security slits to prevent removal of prevent removal of intact labelintact label
Product Authentication:
Color Shifting Ink (Overt Feature)
Product Product Authentication: Authentication:
Color Shifting Ink Color Shifting Ink ((Overt FeatureOvert Feature))
1
Product Authentication:
(Covert Features)
Product Product Authentication: Authentication:
(Covert Features)(Covert Features)
2
Security Feature T-cuts Prevent Label
Re-use
Security Security Feature TFeature T--cuts cuts Prevent Label Prevent Label
ReRe--useuse
3
Product Authentication for the Product Authentication for the Crimp CapCrimp Cap
• Anti-Tampering: provides evidence of first opening(flip off cap)
18Confidential
– Overt Baxter wordmark visible throughout the chain of custody, wallpaper print on the aluminum shell
BioScience Product Integrity Program:BioScience Product Integrity Program:Implementation for All BioScience Products Implementation for All BioScience Products --
• Implementation to mitigate counterfeiting issues
19Confidential
• Proactively, Baxter established the Therapy Integrity Program was to safeguard its products & therapies now –for the future welfare of its patients
• ADVATE and GAMMAGARD LIQUID
AntiAnti--Counterfeiting vs. ePedigreeCounterfeiting vs. ePedigree
Typically anti-counterfeiting measures involve the primary package design, often employing multi-layers of product authentication & security features
ePedigree is a matter of regulatory compliance and provides a means of determining where product is being diverted or counterfeit goods may enter the system
20Confidential
Anti-Counterfeiting
Product integrity features make counterfeiting more difficult and time consuming, making the product less attractive to criminal elements
Product integrity features can help the customer authenticate the product without the use of hardware or electronics
ePedigree
By its nature, e-Pedigree requires electronic equipment/systems to detect or interpret the information
Pedigree ModelsPedigree Models
© Copyright 1995-2007 Baxter Healthcare Corporation. All rights reserved.
21
Normal Chain of Distribution
Florida Pedigree Model
California Pedigree Model
•Pedigree Document Created by Wholesaler•Pedigree Passed to Subsequent Wholesalers•Pedigree Updated and Passed to Customers•Pedigree done at case level•Pedigree Has: Lot # - Exp. Date – Strength –Dosage - Receivers – Legal Signature
•Manufacturer must document wholesaler as Authorized Distributor of Record•Pedigree only required when transaction is outside of Normal Chain•Must be licensed & have contracts
•Pedigree Document Created by Manufacturer•Pedigree Passed to Subsequent Wholesalers•Pedigree Updated and Passed to Customers•Pedigree at each level•Pedigree Has: Unique Serial Number/each•Pedigree Must be Electronic and Interoperable•Drug Must be able to be tracked and traced
Wholesaler
Manufacturer
Customer
Wholesaler
Wholesaler
Manufacturer
Customer
Wholesaler
Wholesaler
Manufacturer
Wholesaler
Customer
21Confidential
• Provides traceability and pedigree– Compliance dates delayed until 2015/2016
Serialization & ePedigreeSerialization & ePedigree
Will provide additional
data on dist. chain once in
place
22Confidential
– Serialization on unit carton, shipper & pallet– Provide product tracking, but will stop short of sending
pedigree data electronically
• Serialization implementation (pilot) will allow tracking of product in manufacturing (facility) & at the 3rd party logistics (distribution)
Page 23
Product and Information Flow:Product and Information Flow:Future State for ePedigree Future State for ePedigree --
Product Flow
Information Flow
Manufacturer Plant
Manufacturer DC
Distributor DC
Hospital / RetailPharmacy
DATA Read Point
• Leverage “2-D barcodes” to capture and track the movement of pallets, cases and individual units through the distribution chain
• Provide up- and downstream inventory visibility through a distributed, standards based data repository
Next StepsNext Steps
• Continued Implementation
24Confidential
– Worldwide across geographies for all products• According to established implementation plans• Developing artwork• Seeking MoH approvals
– Launch label, unit carton, and cap product integrity features simultaneously when possible
– Establish a Product Integrity Business System to mitigate counterfeiting over time
• Monitor Data Streams
Suggestions by Industry ExpertsSuggestions by Industry Experts
25Confidential
Source: Ten Tips to Fight Pharmaceutical Counterfeiting, By Raymond P. Castello, see http://www.pharmamanufacturing.com/articles/2008/071.html
• Monitor Your Processes – Personnel, inventory, & suppliers
• Monitor Your Distribution Chain – Know what is happening to your products
• Distributors, wholesalers, etc.• “You Don’t Know What You Don’t Know”
– Ask questions– Returned goods
• Assess Your Risks – Learn about counterfeiting– Think like a counterfeiter
QualityVision / Mission
StrategicPillars
Product Integrity Program aligns with business objectives to enhance the safety of life-saving therapies and consumer confidenceLead by a Product Integrity Governance Board
Product Integrity Program
Dis
trib
utio
n C
hain
Dis
trib
utio
n C
hain
Lega
l, R
egul
ator
y, e
tc.
Lega
l, R
egul
ator
y, e
tc.
Pro
duct
Aut
hent
icat
ion
Pro
duct
Aut
hent
icat
ion
Product Integrity is an integral part of the business, mitigating risk to the franchise by protecting the integrity of products and therapies for our patients
Product Integrity Program:Product Integrity Program:Concept Concept –– Future StateFuture State
Pac
kagi
ng D
evel
opm
ent
& O
pera
tions
Pac
kagi
ng D
evel
opm
ent
& O
pera
tions
Ris
k M
itiga
tion
Ris
k M
itiga
tion
FoundationalPrinciples
Strategy Statement
Product Integrity Governance Board:Represents the interest of the Business with respect to Product Integrity
Based on Industry
Benchmarking
26Confidential
Saving and Sustaining Lives Worldwide
27Confidential
BioScienceBioScience
Questions ?Questions ?Questions ?